CREB3L4 as a Radioligand Therapy Target
CREB3L4, cAMP responsive element binding protein 3 like 4, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CREB3L4 staining is highest in colorectal cancer (100% of samples positive), pancreatic cancer (100% of samples positive) and breast cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is CREB3L4 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CREB3L4 expression in cancer
Protein expression of CREB3L4 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 1.00 | High | 100% |
| Pancreatic Cancer | 0.89 | High | 100% |
| Breast Cancer | 0.88 | High | 100% |
| Gastric Cancer | 0.88 | High | 100% |
| Prostate Cancer | 0.86 | High | 100% |
| Endometrial Cancer | 0.82 | High | 100% |
| Liver Cancer | 0.81 | High | 100% |
| Ovarian Cancer | 0.78 | High | 100% |
| Melanoma | 0.75 | High | 100% |
| Thyroid Cancer | 0.75 | High | 100% |
| Lung Cancer | 0.70 | High | 100% |
| Bladder Cancer | 0.70 | High | 100% |
| Kidney Cancer | 0.69 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Cervical Cancer | 0.67 | High | 100% |
| Testicular Cancer | 0.61 | High | 92% |
| Skin Cancer | 0.58 | High | 100% |
| Lymphoma | 0.58 | High | 100% |
| Neuroendocrine Tumors | 0.58 | High | 75% |
| Glioma | 0.56 | High | 100% |
Is CREB3L4 internalized?
Nuclens has not yet extracted internalization evidence for CREB3L4. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
CREB3L4 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for CREB3L4 yet. Search ClinicalTrials.gov for CREB3L4 trials.
CREB3L4 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CREB3L4 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CREB3L4 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · FAP · EGFR · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how CREB3L4 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.